Therapy of patients with severe hemophilia (including hemophilia with inhibitors) and other severe bleeding disorders could be monitored and guided based upon special clotting assays , eg thrombin generation and thromboelastography. In this study blood sampled from patients with bleeding disorders will be evaluated applying ex- vivo spiking assays with various coagulation concentrates to potentially address the feasibility of replacement /bypass agents/ combined therapy for future bleeding episodes. Patients that will be further treated by any regimen potentially suggested (as standard care- not within trial) will be thereafter followed , including repeated lab studies to assess the impact of therapy upon hemostasis.
Study Type
OBSERVATIONAL
Enrollment
300
Sheba Mediacl Center
Ramat Gan, Israel
Thrombin Generation Parameters pre and post therapy / spiking assays
Thrombin Generation Parameters (Peak height, ETP) before and after spiking assays with procoagulant drugs will be compared for each patient separately and within each group of patients diagnosed with similar coagulation disorder.
Time frame: 1 year from enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.